Haloperidol Interactions with the dop-3 Receptor in Caenorhabditis elegans

Molecular Neurobiology
Bárbara Nunes KrumMichael Aschner


Haloperidol is a typical antipsychotic drug commonly used to treat a broad range of psychiatric disorders related to dysregulations in the neurotransmitter dopamine (DA). DA modulates important physiologic functions and perturbations in Caenorhabditis elegans (C. elegans) and, its signaling have been associated with alterations in behavioral, molecular, and morphologic properties in C. elegans. Here, we evaluated the possible involvement of dopaminergic receptors in the onset of these alterations followed by haloperidol exposure. Haloperidol increased lifespan and decreased locomotor behavior (basal slowing response, BSR, and locomotion speed via forward speed) of the worms. Moreover, locomotion speed recovered to basal conditions upon haloperidol withdrawal. Haloperidol also decreased DA levels, but it did not alter neither dop-1, dop-2, and dop-3 gene expression, nor CEP dopaminergic neurons' morphology. These effects are likely due to haloperidol's antagonism of the D2-type DA receptor, dop-3. Furthermore, this antagonism appears to affect mechanistic pathways involved in the modulation and signaling of neurotransmitters such as octopamine, acetylcholine, and GABA, which may underlie at least in part haloperidol's effects. T...Continue Reading


Aug 10, 1976·Philosophical Transactions of the Royal Society of London. Series B, Biological Sciences·J G WhiteS Brenner
Sep 15, 1975·The Journal of Comparative Neurology·J SulstonS Brenner
Dec 1, 1994·Experimental Neurology·C A FoxS J Watson
Feb 16, 2002·Methods : a Companion to Methods in Enzymology·K J Livak, T D Schmittgen
Feb 28, 2002·Behavioural Brain Research·Mary V Solanto
Feb 28, 2002·Proceedings of the National Academy of Sciences of the United States of America·Richard NassRandy D Blakely
Jul 31, 2003·Journal of Neurochemistry·Satoshi SuoShoichi Ishiura
Oct 2, 2003·European Journal of Pharmacology·Robert E McCullumsmithJames H Meador-Woodruff
Jan 24, 2004·The EMBO Journal·Suparna SanyalHubert H M Van Tol
Feb 6, 2004·The Journal of Neuroscience : the Official Journal of the Society for Neuroscience·Thomas HillsAndres Villu Maricq
May 21, 2004·Nature Reviews. Neuroscience·Roy A Wise
Aug 18, 2004·Methods in Enzymology·Daniel L Chase, Michael R Koelle
Sep 21, 2004·Nature Neuroscience·Daniel L ChaseMichael R Koelle
Jul 19, 2005·Annual Review of Neuroscience·Mario de Bono, Andres Villu Maricq
Sep 12, 2006·Pharmacological Research : the Official Journal of the Italian Pharmacological Society·Dallas R DonohoeDonard S Dwyer
Oct 5, 2006·Journal of Neural Transmission. Supplementum·O Hornykiewicz
Aug 3, 2007·Progress in Neuro-psychopharmacology & Biological Psychiatry·Roselei FachinettoJuliano Ferreira
Dec 1, 2007·WormBook : the Online Review of C. Elegans Biology·Daniel L Chase, Michael R Koelle
Feb 20, 2008·International Journal of Developmental Neuroscience : the Official Journal of the International Society for Developmental Neuroscience·Dallas R DonohoeDonard S Dwyer
Jul 7, 2009·European Archives of Psychiatry and Clinical Neuroscience·Gerburg KeilhoffAxel Becker
Feb 10, 2011·The EMBO Journal·Marina EzcurraWilliam R Schafer
Jun 22, 2012·PloS One·Daniel T OmuraH Robert Horvitz
Nov 13, 2012·Biological Psychiatry·Allyson V McCormickBrian C Kraemer
Apr 24, 2013·Behavioral and Brain Functions : BBF·Mahlet D MershaSingh Harbinder
Dec 7, 2013·Journal of Molecular Signaling·Pratima PandeyHarbinder S Dhillon
Jan 24, 2014·Metallomics : Integrated Biometal Science·Julia BornhorstMichael Aschner
Feb 25, 2014·Journal of Visualized Experiments : JoVE·Limin Hao, Edgar A Buttner
Apr 22, 2014·Progress in Neuro-psychopharmacology & Biological Psychiatry·Jivago RöpkeRoselei Fachinetto
Jun 10, 2014·The Journal of Clinical Investigation·Freja H HansenUlrik Gether
Apr 8, 2015·Current Opinion in Neurobiology·Mei Zhen, Aravinthan D T Samuel
Jan 27, 2016·Progress in Molecular Biology and Translational Science·Eric A EnglemanBethany S Neal-Beliveau
Feb 28, 2016·Developmental Biology·Takashi NagashimaSatoshi Suo
Jun 1, 2014·Bioscience·Julijana GjorgjievaGal Haspel
Apr 12, 2017·Progress in Neuro-psychopharmacology & Biological Psychiatry·Qingzhong WangYogesh Dwivedi
Jun 30, 2017·Frontiers in Genetics·Malabika MaulikElena M Vayndorf
Aug 1, 2017·European Neuropsychopharmacology : the Journal of the European College of Neuropsychopharmacology·Óskar HálfdánarsonChristian J Bachmann
Jan 29, 2018·Pharmacology, Biochemistry, and Behavior·Ana Paula Chiapinotto CerettaRoselei Fachinetto
Jan 12, 2019·Movement Disorders : Official Journal of the Movement Disorder Society·Danielle E MorHarry Ischiropoulos
Jun 20, 2019·Current Protocols in Neuroscience·Fausto Pierdoná GuzenDayane Pessoa de Araújo


Jan 12, 2021·Neurobiology of Disease·Antonio Dominguez-MeijideTiago Fleming Outeiro

Methods Mentioned

reverse transcription PCR

Related Concepts

Mental Disorders
Gamma-Aminobutyric Acid
Gene Expression

Related Feeds

Antipsychotic Drugs

Antipsychotic drugs are a class of medication primarily used to manage psychosis (including delusions, hallucinations, paranoia or disordered thought), principally in schizophrenia and bipolar disorder. Discover the latest research on antipsychotic drugs here

Basal Forebrain- Circuits

Basal forebrain is a region in the brain important for production of acetylcholine and is the major cholinergic output of the CNS. Discover the latest research on circuits in the basal forebrain here.

Related Papers

Krankenpflege Journal
D Blumenberg
The Medical Journal of Australia
W Inglis
The Medical Letter on Drugs and Therapeutics
The Medical Journal of Australia
R McMurdo
Gaceta médica de México
R Rodríguez-Carranza
© 2021 Meta ULC. All rights reserved